Renal Cell Carcinoma News and Research

Latest Renal Cell Carcinoma News and Research

Consortium database model compares favorably for RCC prognosis

The International Metastatic Renal-Cell Carcinoma Database has been externally validated and is now ready for application, researchers report.

20 Feb 2013

COX-2 inhibitor extends sunitinib activity in renal cell carcinoma

The effectiveness of sunitinib for the treatment of renal cell carcinoma could be enhanced with the addition of a cyclooxygenase-2 inhibitor, study findings show.

20 Feb 2013

Metastatic tumors best for sunitinib response evaluation in mRCC

When evaluating treatment response in non-nephrectomized patients with metastatic renal cell carcinoma, the primary lesion does not have to be selected as the target lesion, researchers report.

20 Feb 2013

Possible alternative to biopsy discovered for renal cancer diagnosis

Combining positron emission tomography scanning with iodine-124 (124I)–girentuximab may offer an effective noninvasive method of diagnosing clear cell renal cell carcinoma in patients who present with a renal mass, US study results suggest.

20 Feb 2013

Tivozanib overall survival results announced by AVEO and Astellas

AVEO Oncology (NASDAQ: AVEO) and Astellas Pharma Inc. (TSE: 4503) announced overall survival (OS) for tivozanib, an investigational agent, from the Phase 3 TIVO-1 (TIvozanib Versus sOrafenib in 1st line advanced RCC) study in patients with advanced renal cell carcinoma (RCC). The final OS analysis, as specified by the protocol, shows a median OS of 28.8 months (95% confidence interval [CI]: 22.5–NA) for tivozanib versus a median OS of 29.3 months (95% CI: 29.3–NA) for the comparator arm, sorafenib.

13 Feb 2013

Metastatic renal cell carcinoma (mRCC) therapy: an interview with Charles A. Nicolette, Ph.D., CSO of Argos Therapeutics

Metastatic renal cell carcinoma is a devastating disease. There are roughly 20-25,000 new cases per year in the United States and it is increasing for some reason.

12 Feb 2013

Sunitinib does not cause lingering risks for cancer patients after their treatment ends

Studies in animals have raised concerns that tumors may grow faster after the anticancer drug sunitinib is discontinued. But oncologists and physicists who collaborated to analyze data from the largest study of patients with kidney cancer convincingly demonstrate that such tumor acceleration does not occur in humans.

10 Feb 2013

Sunitinib shows promise against metastatic renal cell carcinoma

Findings from clinical trial patients with metastatic renal cell carcinoma, a common kidney cancer, show they did not have accelerated tumor growth after treatment with sunitinib, in contrast to some study results in animals. Sunitinib is one of several drugs, either on the market or undergoing testing, that target blood vessel growth.

10 Feb 2013

Acceleron commences dalantercept phase 2 study in metastatic renal cell carcinoma

Acceleron Pharma, Inc., a biopharmaceutical company developing protein therapeutics for cancer and orphan diseases, announced the initiation of a phase 2 study of dalantercept, a novel angiogenesis inhibitor that targets the activin receptor-like kinase 1 (ALK1) pathway.

5 Feb 2013

Acceleron Pharma initiates dalantercept phase 2 study in advanced ovarian cancer

Acceleron Pharma, a biopharmaceutical company developing protein therapeutics for cancer and orphan disease, today announced that the Gynecologic Oncology Group (GOG) initiated a phase 2 study of dalantercept in patients with persistent or recurrent ovarian, fallopian tube, or primary peritoneal cancer.

5 Feb 2013

Oral toxicity is frequent limitation of mTOR therapy

Oral mucositis is a frequent complication in patients taking mTOR inhibitors and a major reason for dose reductions and discontinuations in clinical trials, according to a review of this class of cancer drugs.

4 Feb 2013

$Bayer, Onyx announce data from Nexavar Phase 3 trial on RAI-refractory differentiated thyroid cancer$

Bayer, Onyx announce data from Nexavar Phase 3 trial on RAI-refractory differentiated thyroid cancer

Bayer HealthCare Pharmaceuticals and Onyx Pharmaceuticals, Inc. today announced that a Phase 3 trial of Nexavar (sorafenib) tablets in patients with locally advanced or metastatic radioactive iodine-refractory (RAI) differentiated thyroid cancer has met its primary endpoint of a statistically significant improvement of progression-free survival.

3 Jan 2013

Cytokine rise signals RCC progression

Progression of renal cell carcinoma is frequently preceded by a rise in levels of proangiogenic cytokines, Italian researchers have found.

17 Dec 2012

Nephron-sparing surgery beats ablation for small renal masses

Nephron-sparing surgery is more effective than ablation for the treatment of clinical stage T1a renal masses, research findings show.

17 Dec 2012

Preop features predict pathology of small renal masses

Researchers have identified preoperative clinical and tumor characteristics that predict the risk for malignancy in patients undergoing partial nephrectomy for small renal masses.

17 Dec 2012

Partial nephrectomy maintains renal function in cT1a RCC

Partial nephrectomy offers a similar magnitude of benefit in patients with clinical T1b versus cT1a renal cell carcinoma, Japanese researchers have shown.

17 Dec 2012

Kidney cancer survival rates: an interview with Dr Wong-Ho Chow

There are two major forms of kidney cancer. One is called renal cell cancer, which is an adenocarcinoma that occurs in the renal parenchyma. The other major type is called renal pelvis cancer, which is mostly of transitional cell type and they form in the centre of the kidney where the urine collects.

7 Dec 2012

Researchers discover 29 proteins associated with spread of kidney cancer

Researchers at St. Michael's hospital have identified 29 proteins that are likely to be involved in the spread of kidney cancer. The discovery will help physicians recognize which tumours are going to behave more aggressively and provide those patients with more intensive treatment and closer followup.

7 Dec 2012

Novartis to highlight key data from extensive oncology portfolio at SABCS and ASH meeting

Novartis will highlight more than 140 presentations on key data from its extensive oncology portfolio at the leading year-end scientific meetings devoted to hematology and breast cancer, demonstrating continued innovation in research and development efforts to advance the care of patients with cancer and rare diseases.

30 Nov 2012

Perfusion of renal masses on MR corresponds to histopathologic diagnosis

A magnetic resonance imaging technique that uses blood as a contrast medium is able to distinguish between different histopathologic diagnoses of solid renal masses based on their perfusion level, claims a team of scientists.

22 Nov 2012